Clinical trial
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
NCT00447330 is registered in ClinicalTrials.gov with Duke University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
- Lead sponsor
- Duke University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2007
- Completion date
- July 31, 2014
- Enrollment
- 60 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.